Modification of gene activity in mouse embryos in utero by a tamoxifen-inducible form of Cre recombinase

Current Biology

Volumn 8, Issue 24, 1998, Pages 1323-1326

  Danielian, Paul S ^a,b   Muccino, David ^a   Rowitch, David H ^a,c   Michael, Simon K ^a,d   McMahon, Andrew P ^a  

^a HARVARD UNIVERSITY   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 0032481124     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0960-9822(07)00562-3     Document Type: Article

References (15)

1. Porter A: Controlling your losses: conditional gene silencing in mammals. Trends Genet 1998, 14:73-79.
2. Metzger D, Clifford J, Chiba H, Chambon P: Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase. Proc Natl Acad Sci USA 1995, 92:6991-6995.
3. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, Chambon P: Ligand-activated site-specific recombination in mice. Proc Natl Acad Sci USA 1996, 93:10887-10890.
4. Kellendonk C, Tronche F, Monaghan AP, Angrand PO, Stewart F, Schutz G: Regulation of Cre recombinase activity by the synthetic steroid RU 486. Nucleic Acids Res 1996, 24:1404-1411.
5. Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, Reth M: Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res 1996, 24:543-548.
6. Echelard Y, Vassileva G, McMahon AP: Cis-acting regulatory sequences governing Wnt-1 expression in the developing mouse CNS. Development 1994, 120:2213-2224.
7. Lee SM, Danielian PS, Fritzsch B, McMahon AP: Evidence that FGF8 signalling from the midbrain-hindbrain junction regulates growth and polarity in the developing midbrain. Development 1997, 124:959-969.
8. Fawell SE, Lees JA, White R, Parker MG: Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 1990, 60:953-962.
9. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG: Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 1993, 7:232-240.
10. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995, 23:1686-1690.
11. Mattioni T, Louvion JF, Picard D: Regulation of protein activities by fusion to steroid binding domains. Methods Cell Biol 1994, 43:335-352.
12. Brocard J, Warot X, Wendling O, Messaddeq N, Vonesch JL, Chambon P, Metzger D: Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc Natl Acad Sci USA 1997, 94:14559-14563.
13. Schwenk F, Kuhn R, Angrand PO, Rajewsky K, Stewart AF: Temporally and spatially regulated somatic mutagenesis in mice. Nucleic Acids Res 1998, 26:1427-1432.
14. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 1990, 11:578-610.
15. Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient Drug Metab Dispos 1991, 19:36-43.